NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Rapid Micro Biosystems, Inc. (RPID) Stock Analysis

Rapid Micro Biosystems, Inc. (RPID) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

RPID

$1.31

−$0.07 (−5.07%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RPID with… →

RPID Key Statistics

As of Sep 4, 2026
Trading
Open
$1.37
Previous Close
$1.38
Day's Range
1.29–1.49
52-Week Range
1.29–4.94
Volume
378.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.44
Valuation
Market Cap
$65.71M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.87
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.11
Financials (FY)
Revenue (FY)
$33.59M+19.74%
Net Income (FY)
−$47.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
−145.55%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.66M
1-Year Return
−46.31%
Dividend and dates
Earnings Date
November 6, 2026estimated
Avg Volume
210.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RPID Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−54.83%
2025+222.22%
2024+21.62%
2023−34.51%
2022−89.38%
2021 (partial year)−50.28%

As of September 4, 2026.

RPID Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$33.59M−$47.12M−140.3%
2024$28.05M−$46.89M−167.2%
2023$22.52M−$52.47M−233.0%
2022$17.13M−$60.81M−354.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$33.59M$1.05M−$47.39M−$47.12M−140.3%
2024$28.05M−$109.00K−$49.92M−$46.89M−167.2%
2023$22.52M−$5.49M−$56.56M−$52.47M−233.0%
2022$17.13M−$8.54M−$63.22M−$60.81M−354.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RPID Valuation vs Medical Devices Median

Median of 151 stocks
MetricRPIDMedical Devices medianvs median
P/S ratio1.872.9837% below
Profit margin−145.55%−1.69%143.9 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Rapid Micro Biosystems, Inc. (RPID) carries a market capitalisation of $65.71M. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 171 employees.

The 52-week range on file runs from $1.29 to $4.94. The most recent close on file for RPID is $1.31, dated September 4, 2026. That is −$0.07 (−5.07%) against the previous close. The latest close sits 1.55% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $33.59M. Against the prior fiscal year total of $28.05M, that is a change of +19.74%. The same year closed with a net loss of $47.12M. Profit margin runs at −145.55%. That is 143.9 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −1.11.

Across the 4 fiscal years on file, revenue moves from $17.13M in 2022 to $33.59M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1.87 times revenue. On price-to-sales that is 37.23% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned −46.31%. Measured over 5 years, that is −41.50% a year compounded. Beta against the wider market is reported at 1.44. Daily returns over the trailing 5 years annualize to a volatility of 86.09%.

Growth & Income

No dividend is on file for RPID.

So far in 2026 the price is −54.83%. The strongest complete calendar year on file is 2025 at +222.22%; the weakest is 2022 at −89.38%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Rapid Micro Biosystems, Inc. (RPID) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rapid Micro Biosystems, Inc. RPID $65.71M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Rapid Micro Biosystems, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Visit website →